Industry
Biotechnology
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 7:58 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 6:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 8:35 pm
Portfolio Pulse from Dylan Berman
June 25, 2024 | 4:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 8:35 pm
Portfolio Pulse from Avi Kapoor
June 21, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 8:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.